Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
CA 2295237 A1 · Owner: Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group · Inventors: Gudmundsdottir, Vera; Gizurarson, Sveinbjorn
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Adjuvants for administration, particularly for mucosal administration of an , antigen, are described, as well as compositions comprising the described adjuvant in combination with an antigen and a physiologically acceptable vehicle. Methods of eliciting and enhancing an immune response utilizing the adjuvant compositions of the invention are also described. The adjuvant comprises mono- or diglycerides containing at least one water soluble polymer e.g. poly oxyethylene (PEG2-30). The antigen can be bound to the adjuvant. The adjuvant may be used in the treatment of plants as well.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 9, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.